MedTrace Logo

PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

NCT00319865 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2006-04-27

No results posted yet for this study

Summary

Prospective multicenter phase 2 study using PAD and Thal/Dex combination sequentially.

Conditions

Interventions

DRUG

Velcade

DRUG

Thalidomide

DRUG

Adriamycin

DRUG

Dexamethasone

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Korean Multiple Myeloma Working Party

    lead OTHER

Principal Investigators

  • Jae Hoon Lee, M.D. · Korean Multiple Myeloma Working Party

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Completion
2008-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00319865 on ClinicalTrials.gov